The Affiliated Cancer Hospital of Xiangya School of Medicine(Hunan Cancer Hospital )
Welcome,         Profile    Billing    Logout  
 1 Trial 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Weiqing
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Active, not recruiting
3
528
RoW
TQB2450, Anlotinib, Sunitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Renal Cancer
06/25
12/25
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Recruiting
2
58
RoW
MRG002
Shanghai Miracogen Inc.
Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
06/22
09/22
NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting
2
110
RoW
HX008
Taizhou Hanzhong biomedical co. LTD
Bladder Cancer
12/22
12/23
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Recruiting
2
115
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Bladder Urothelial Cancer
12/24
06/25
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Recruiting
1/2
114
RoW
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
09/24
12/24
NCT05416749: A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
216
RoW
8MW2311
Mabwell (Shanghai) Bioscience Co., Ltd.
Solid Tumors
03/26
03/26
NCT04664725: Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Recruiting
1
18
RoW
Repaglinide, Bupropion and SHR3680
Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer Patients
01/21
05/21
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Recruiting
1
120
RoW
Genakumab, Tislelizumab
GeneScience Pharmaceuticals Co., Ltd.
Malignant Solid Tumors
06/24
03/25

Download Options